Liquidia Corporation
LQDA
Rank in Stocks
#4841
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Share Price
$34.12
Last synced: 2026-10-19
Market Cap
$3.05B
Change (1 day)
-0.67%
Change (1 year)
39.61%
Country
US
Trade Liquidia Corporation (LQDA)
Category
Healthcare
P/B ratio for Liquidia Corporation (LQDA)
P/B ratio as of October 2026 TTM: 15.46
According to Liquidia Corporation latest financial reports and stock price the company's current price-to-book ratio (TTM) is 15.46. At the end of 2023 the company had a P/B ratio of 16.53.
P/B ratio history for Liquidia Corporation from 2016 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 15.46 | 29.07% |
| 2024 | 11.98 | -27.55% |
| 2023 | 16.53 | 284.98% |
| 2022 | 4.29 | -649.51% |
| 2021 | -0.78 | -155.57% |
| 2020 | 1.41 | -37.80% |
| 2019 | 2.26 | -72.77% |
| 2018 | 8.30 | -393.49% |
| 2017 | -2.83 | -45.85% |
| 2016 | -5.22 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 3.8424 | -75.15% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 2.4753 | -83.99% |
HK
|
